REGISTER
Dr Kohei Shitara at ASCO 2025 -- MedJ Interview
Dr Kohei Shitara at ASCO 2025 -- MedJ Interview is examined through new evidence rather than broad claims. The summary connects evidence on ASCO, III, kohei with who may benefit, what risks matter most, and how practice could change.

MedJ takes you straight to ASCO 2025.

Professor Kohei Shitara from Japan's National Cancer Center reported the global Phase III breakthrough of trastuzumab deruxtecan in treating HER2-positive gastric cancer at the 2025 ASCO Annual Meeting.

0
0
Loading